1. Replimune facing class action lawsuit over alleged misleading statements. 2. Claims concern IGNYTE trial's prospects and regulatory compliance failures. 3. Shareholders can register to join the lawsuit by September 22, 2025. 4. Gross Law Firm is managing the class action for affected investors. 5. Appointment as lead plaintiff not required for recovery participation.
The lawsuit indicates potentially serious issues with the company's credibility and operations, similar to past cases impacting firms negatively. Historically, when a significant lawsuit is announced, affected companies often see a decline in stock price.
The class action lawsuit directly affects investor trust and confidence, significantly impacting stock performance. Legal issues in biopharma often lead to heightened volatility.
The immediate impact is likely as investors may react quickly to legal issues. Previous cases in biopharma, like with Axovant Gene Therapies, show short-lived but sharp price drops upon lawsuit announcements.
NEW YORK, Aug. 18, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ:REPL).
Shareholders who purchased shares of REPL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CONTACT US HERE:
CLASS PERIOD: November 22, 2024 to July 21, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants recklessly overstated the IGNYTE trial's prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants' statements about Replimune's business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
DEADLINE: September 22, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/replimune-group-inc-loss-submission-form-3/?id=161645&from=4
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of REPL during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 22, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (646) 453-8903
View original content to download multimedia:https://www.prnewswire.com/news-releases/contact-the-gross-law-firm-by-september-22-2025-deadline-to-join-class-action-against-replimune-group-increpl-302531141.html
SOURCE The Gross Law Firm